RE: Report out today20 Feb 2023 08:46
Commenting on the interim results, Paul Swinney, Chief Executive of Tristel, said: "We are delighted to have increased sales by 16% on the first half of last year, above our long-term target for revenue growth.
In all regions the level of diagnostic examinations utilising our products is significantly higher than before the commencement of the pandemic.
We have now entered the North American market, having launched Duo Ophthalmology in Canada, and Duo Ultrasound in the USA under our EPA approval, and expect the FDA's decision on our De Novo submission in June.
The growth prospects for the Group are stronger than ever and we look to the future with confidence."
https://www.londonstockexchange.com/news-article/TSTL/half-year-report/15843025